Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 18/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.70 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533300 | 0.93 | HTR1A (0.87) | HTR1A | |
| SCHEMBL4546540 | 0.87 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL5184178 | 0.87 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL30628143 | 0.87 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL5199919 | 0.85 | HTR1A (1.00) | HTR1A | |
| SCHEMBL13533292 | 0.85 | HTR1A (0.73) | HTR1A | |
| SCHEMBL5184122 | 0.85 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL13533280 | 0.84 | HTR1A (0.73) | HTR1A | |
| SCHEMBL3904984 | 0.83 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL5184137 | 0.83 | HTR1A (1.00) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | claimed |
| CN-1098263-C | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2003-01-08 | — | — | CN | claimed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | claimed |
| CN-1242772-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2000-01-26 | — | — | CN | claimed |
| US-8609694-B2 | Use of pyridin-2-yl-methylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin | PIERRE FABRE MEDICAMENT (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1603564-B1 | USE OF PYRIDIN-2-YLMETHYLAMINE DERIVATIVES FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC NEUROPATHOLOGICAL OR PSYCHOGENIC PAIN SYMPTOMS | PF MEDICAMENT (FR) | 2007-07-04 | — | — | EP | disclosed |
| US-20060241141-A1 | Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin | PIERRE FABRE MEDICAMENT (FR) | 2006-10-26 | — | — | US | disclosed |
| EP-1603564-A2 | USE OF PYRIDIN-2-YLMETHYLAMINE DERIVATIVES FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC NEUROPATHOLOGICAL OR PSYCHOGENIC PAIN SYMPTOMS | PIERRE FABRE MEDICAMENT (FR) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083171-A2 | USE OF PYRIDIN-2-YLMETHYLAMINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEUROPATHOLOGICAL OR PSYCHOGENIC PAIN SYMPTOMS | PIERRE FABRE MEDICAMENT (FR) | 2004-09-30 | — | — | WO | disclosed |
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | disclosed |
| CN-1098263-C | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2003-01-08 | — | — | CN | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885DRD2 242/4885DRD4 301/4885 |
| US-20060241141-A1 | Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin | PNMT, HTR2C, PYGB | HTR1A 20/4885DRD2 394/4885DRD4 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.